"...Furthermore, 10 million in funding will be granted to the Jin Pharmaceutical Group for its new primary cancer treatment drug, the Banzhe Project, and to Wu's Pharmaceutical Company for its Fengmu Tiada project... At the same time, the foundation will also evaluate and accept applications for funding from other domestic pharmaceutical companies for new drug research projects that meet the criteria for independent research and development..."
Of course, in addition to these penalties, an official announcement was also posted on the official website:
The 7 substandard drugs announced by the Drug Administration:
First: Nanhuai Haoyao Pharmaceutical Co., Ltd.'s Fluocinonide Acetate and Borneol Cream
Second: Guangtian Pharmaceutical Company's Cortisone Acetate Eye Drops
...
Sixth: Southern Country's Ruihui Pharmaceutical's Sorafenib
...
Such an announcement would be recorded in the database, existing forever, permanently searchable—an indelible stain!
...
...
